CN107722095B - 化合物Dictyopterisin I在制备抗肿瘤药物中的应用 - Google Patents
化合物Dictyopterisin I在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN107722095B CN107722095B CN201710940779.9A CN201710940779A CN107722095B CN 107722095 B CN107722095 B CN 107722095B CN 201710940779 A CN201710940779 A CN 201710940779A CN 107722095 B CN107722095 B CN 107722095B
- Authority
- CN
- China
- Prior art keywords
- compound
- undulata
- drugs
- preparation
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title abstract description 15
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 9
- 229940041181 antineoplastic drug Drugs 0.000 title abstract description 9
- LHQIJBMDNUYRAM-CVYQJGLWSA-N 2-amino-6-[(1r,2r)-1,2-dihydroxypropyl]-1h-pteridin-4-one Chemical compound N1C(N)=NC(=O)C2=NC([C@@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-CVYQJGLWSA-N 0.000 title description 2
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 7
- OFPZNTXZCGKCMU-VXBOPZJTSA-N (3z,5e,7r,8s,10s,11z,13s,14r,15s,17s,20r,21s,22s)-22-[(2s,3z)-hexa-3,5-dien-2-yl]-8,10,14,20-tetrahydroxy-7,13,15,17,21-pentamethyl-1-oxacyclodocosa-3,5,11-trien-2-one Chemical compound C=C\C=C/[C@H](C)[C@@H]1OC(=O)\C=C/C=C/[C@@H](C)[C@@H](O)C[C@H](O)\C=C/[C@H](C)[C@H](O)[C@@H](C)C[C@@H](C)CC[C@@H](O)[C@@H]1C OFPZNTXZCGKCMU-VXBOPZJTSA-N 0.000 claims description 17
- OFPZNTXZCGKCMU-QUQSCIKMSA-N Dictyostatin 1 Natural products CC(C=C/C=C)C1OC(=O)C=C/C=C/C(C)C(O)CC(O)C=C/C(C)C(O)C(C)CC(C)CCC(O)C1C OFPZNTXZCGKCMU-QUQSCIKMSA-N 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 11
- 239000000243 solution Substances 0.000 abstract description 10
- 238000012360 testing method Methods 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 7
- 241000024430 Dictyopteris undulata Species 0.000 abstract description 6
- -1 steroid compound Chemical class 0.000 abstract description 6
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 abstract description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 5
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 abstract description 5
- 201000005202 lung cancer Diseases 0.000 abstract description 5
- 208000020816 lung neoplasm Diseases 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 3
- 239000000839 emulsion Substances 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 3
- 238000007918 intramuscular administration Methods 0.000 abstract description 3
- 238000001990 intravenous administration Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 239000006187 pill Substances 0.000 abstract description 3
- 239000003826 tablet Substances 0.000 abstract description 3
- 235000005807 Nelumbo Nutrition 0.000 abstract description 2
- 240000002853 Nelumbo nucifera Species 0.000 abstract description 2
- 230000005918 in vitro anti-tumor Effects 0.000 abstract description 2
- 239000000375 suspending agent Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000010828 elution Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000199915 Dictyotaceae Species 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- GJYVZUKSNFSLCL-UHFFFAOYSA-N dichloromethanol Chemical compound OC(Cl)Cl GJYVZUKSNFSLCL-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002611 lead compounds Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000011894 semi-preparative HPLC Methods 0.000 description 3
- 229930004725 sesquiterpene Natural products 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- OFNXOACBUMGOPC-HZYVHMACSA-N 5'-hydroxystreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](CO)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O OFNXOACBUMGOPC-HZYVHMACSA-N 0.000 description 1
- GKBHKNPLNHLYHT-UHFFFAOYSA-N 5beta-Stigmastan Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 GKBHKNPLNHLYHT-UHFFFAOYSA-N 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000224495 Dictyostelium Species 0.000 description 1
- 241000199916 Dictyotales Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 108010054050 Plectin Proteins 0.000 description 1
- 102000056300 Plectins Human genes 0.000 description 1
- 241000206609 Porphyra Species 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- OFNXOACBUMGOPC-UHFFFAOYSA-N hydroxystreptomycin Natural products CNC1C(O)C(O)C(CO)OC1OC1C(C=O)(O)C(CO)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O OFNXOACBUMGOPC-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- OKPOKMCPHKVCPP-UHFFFAOYSA-N isoorientaline Natural products C1=C(O)C(OC)=CC(CC2C3=CC(OC)=C(O)C=C3CCN2C)=C1 OKPOKMCPHKVCPP-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- JTQHYPFKHZLTSH-UHFFFAOYSA-N reticulin Natural products COC1CC(OC2C(CO)OC(OC3C(O)CC(OC4C(C)OC(CC4OC)OC5CCC6(C)C7CCC8(C)C(CCC8(O)C7CC=C6C5)C(C)O)OC3C)C(O)C2OC)OC(C)C1O JTQHYPFKHZLTSH-UHFFFAOYSA-N 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- LAGFCVRVICMFFF-UHFFFAOYSA-N stigmastane Natural products CCC(CCC(C)C1CCC2C3CCC4CC(=O)CC(C)C4C3CCC12C)C(C)C LAGFCVRVICMFFF-UHFFFAOYSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710940779.9A CN107722095B (zh) | 2017-10-11 | 2017-10-11 | 化合物Dictyopterisin I在制备抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710940779.9A CN107722095B (zh) | 2017-10-11 | 2017-10-11 | 化合物Dictyopterisin I在制备抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107722095A CN107722095A (zh) | 2018-02-23 |
CN107722095B true CN107722095B (zh) | 2020-06-09 |
Family
ID=61210220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710940779.9A Active CN107722095B (zh) | 2017-10-11 | 2017-10-11 | 化合物Dictyopterisin I在制备抗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107722095B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104497090A (zh) * | 2014-11-03 | 2015-04-08 | 南昌大学 | 蕨藻烯酮及其制备方法和用途 |
CN107652347A (zh) * | 2017-10-11 | 2018-02-02 | 南昌大学 | 化合物DictyopterisinI及其在制备糖尿病或肥胖症药物中的用途 |
-
2017
- 2017-10-11 CN CN201710940779.9A patent/CN107722095B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104497090A (zh) * | 2014-11-03 | 2015-04-08 | 南昌大学 | 蕨藻烯酮及其制备方法和用途 |
CN107652347A (zh) * | 2017-10-11 | 2018-02-02 | 南昌大学 | 化合物DictyopterisinI及其在制备糖尿病或肥胖症药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN107722095A (zh) | 2018-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110452249B (zh) | 新吉玛烷型倍半萜内酯类化合物及其制备和应用 | |
CN106631775A (zh) | 化合物cytosporaphenone A及其制备方法和在制备抗肿瘤药物中的应用 | |
Jiang et al. | Isoprenylated cyclohexanoids from the basidiomycete Hexagonia speciosa | |
CN107722096B (zh) | 一种具有抗肿瘤作用的甾体类天然药物及其制备方法和用途 | |
CN101463058A (zh) | 羊毛脂烷型三萜化合物海莲酸、其衍生物及其制备方法和用途 | |
CN108689851B (zh) | 一类惕各烷型二萜化合物及其制备方法和应用 | |
JP3639973B2 (ja) | スポンギスタチン6 | |
CN107746421B (zh) | 化合物dictyopterisin f及其在制备抗肿瘤药物中的应用 | |
CN109608419B (zh) | 从青龙衣中提取的二芳基庚烷类化合物及其制备方法和应用 | |
CN107722095B (zh) | 化合物Dictyopterisin I在制备抗肿瘤药物中的应用 | |
CN107722097B (zh) | 抗肿瘤化合物dictyopterisinh及其制备方法和用途 | |
CN107722094B (zh) | 一种甾体类天然药物及其在制备抗肿瘤药物中的用途 | |
CN114436802A (zh) | 一种杜松烷倍半萜化合物及其制备方法和应用 | |
CN107226820A (zh) | 一种具有抗肿瘤作用的毛菌素j及其制备方法与用途 | |
CN113402529B (zh) | 三聚愈创木烷型倍半萜类化合物及其制备方法和应用 | |
Berger | Isolation, characterization, and synthesis of bioactive natural products from rainforest flora | |
CN115785116B (zh) | 三个新颖骨架杜松烷型倍半萜氧桥二聚体的制备方法与应用 | |
CN113024494B (zh) | 一种菲类化合物、制备方法及应用 | |
CN111995560B (zh) | 一种单萜吲哚类化合物及其制备方法和应用 | |
CN108299178B (zh) | 愈创木烷型倍半萜b及其制备方法和作为制备预防肿瘤和抗肿瘤药物的应用 | |
CN116375776A (zh) | 具有抗肿瘤活性的棒节石斛倍半萜苷化合物及其制备方法和应用 | |
RU2367431C1 (ru) | Способ получения лавандозида | |
CN116120334A (zh) | 芫花花蕾中的二萜类化合物及其制备方法和应用 | |
CN1699401B (zh) | 抗癌活性化合物及其提取方法 | |
CN100422167C (zh) | 环己酮类饱和双环(桥环)化合物及其制备方法与用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Xiaoqing Inventor after: Gu Ting Inventor after: Mao Shuichun Inventor after: Feng Meitang Inventor after: Guo Yuewei Inventor before: Mao Shuichun Inventor before: Feng Meitang Inventor before: Guo Yuewei |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210204 Address after: 201111 room e268, 2nd floor, building 3, 2118 Guanghua Road, Minhang District, Shanghai Patentee after: Shanghai Yaoda Biotechnology Co.,Ltd. Address before: 999 No. 330031 Jiangxi province Nanchang Honggutan University Avenue Patentee before: Nanchang University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240102 Address after: Room 303-9, Building 10, No. 2168 Chenhang Road, Minhang District, Shanghai, 201114 Patentee after: Lingyao Biotechnology (Shanghai) Co.,Ltd. Address before: 201111 room e268, 2nd floor, building 3, 2118 Guanghua Road, Minhang District, Shanghai Patentee before: Shanghai Yaoda Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right |